Wegovy vs Mounjaro: Which Weight Loss Treatment Suits You?
Compare Wegovy and Mounjaro: Understanding Prescription Weight Loss Mechanisms
When you compare Wegovy and Mounjaro for prescription weight loss, the fundamental difference lies in their receptor targeting mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural fullness hormone to reduce appetite and promote satiety after smaller meals. This single-target approach has been extensively studied in the STEP clinical trial programme, demonstrating its effectiveness as a prescription-only medicine for weight management.
Mounjaro takes a different approach with tirzepatide, functioning as a dual agonist targeting both GIP and GLP-1 receptors simultaneously. This broader mechanism may influence blood sugar regulation alongside appetite control, though both treatments require prescription oversight and work best when combined with lifestyle modifications. Understanding these mechanistic differences helps explain why some patients respond differently to each treatment when comparing Wegovy and Mounjaro options.
Compare Wegovy and Mounjaro Pricing: UK Prescription Weight Loss Costs
Transparent pricing makes it easier to compare Wegovy and Mounjaro costs for your prescription weight loss journey. Wegovy starts at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our convenient bundle options include the Intro Duo (0.25mg & 0.5mg) at £169.99 and the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99, providing seamless dose progression.
New customers benefit from code FIRST40 applied at checkout, whilst returning customers use code DOSE25 to reach these final prices. When you compare Wegovy and Mounjaro pricing structures, both require similar step-up dosing protocols, though Wegovy's established UK availability through our GPhC-registered pharmacy (#9012878) ensures consistent supply. Bundle pricing reflects convenience rather than savings, ensuring uninterrupted treatment progression without multiple ordering requirements.
Clinical Evidence When You Compare Wegovy and Mounjaro Studies
The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness in prescription weight loss applications. STEP 1 demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo treatment. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, adding significant clinical value beyond weight management.
When comparing clinical evidence, it's important to note that Wegovy and Mounjaro trials used different populations, endpoints, and study designs, making direct percentage comparisons inappropriate. Both treatments have demonstrated significant efficacy in their respective clinical programmes, and individual response varies considerably. Your prescriber can help interpret this evidence when you compare Wegovy and Mounjaro suitability for your specific circumstances.
How Wegovy Works: GLP-1 Receptor Mechanism for Weight Loss
Wegovy's mechanism centres on GLP-1 receptor activation, which occurs naturally when you eat but diminishes in some individuals with weight management challenges. This prescription-only medicine mimics the action of glucagon-like peptide-1, binding to receptors in your brain's appetite centres to reduce food cravings and promote earlier satiety signals. The once-weekly injection delivers consistent semaglutide levels, maintaining appetite suppression throughout the week. Unlike rapid-acting medications, Wegovy works gradually to retrain your eating patterns and portion recognition. This sustained approach explains why the treatment requires dose escalation over 16 weeks to reach the 2.4mg maintenance level. The mechanism specifically targets the biological drivers of overeating rather than simply suppressing appetite temporarily.
Ordering Process: Getting Your Prescription Weight Loss Treatment
Starting your prescription weight loss journey involves a streamlined 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review your application within 3 working days (or 24 hours with express service), ensuring appropriate clinical oversight for this prescription-only medicine. Once approved, your Wegovy ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit. The process includes comprehensive injection training materials and ongoing support throughout your treatment progression. Payment processing accepts all major cards, with discount codes FIRST40 or DOSE25 applied automatically at checkout to reach the listed prices.
Storage and Practical Considerations for Wegovy Treatment
Wegovy requires refrigeration at 2-8°C before first use, but offers superior travel convenience with 6 weeks room temperature tolerance below 30°C once removed from the fridge. This storage advantage becomes significant when you compare Wegovy and Mounjaro's 21-day room temperature limit, particularly for frequent travellers or those with unreliable refrigeration. The FlexTouch pen design provides intuitive injection administration with pre-set doses, eliminating measurement errors common with vial-based systems. Dose escalation follows a mandatory schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), then 2.4mg maintenance. Each pen contains four doses, administered once weekly on the same day, with injection sites rotated between abdomen, thigh, and upper arm. The pen's dose counter and injection confirmation provide clear feedback for successful administration.
Compare Wegovy and Mounjaro: Dual Agonist vs Single Target Approach
The choice between single-target and dual-target mechanisms represents a key consideration when you compare Wegovy and Mounjaro for prescription weight loss. Wegovy's focused GLP-1 approach provides well-established efficacy with extensive real-world experience, whilst Mounjaro's dual GIP/GLP-1 targeting offers theoretical advantages for patients with concurrent metabolic concerns. Both treatments require identical lifestyle commitments and clinical monitoring, making the mechanistic difference more relevant for specific patient profiles.
Individual response patterns vary significantly between treatments, with some patients experiencing better tolerance or efficacy with one approach over another. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to help determine which mechanism aligns better with your medical history and treatment goals. The decision often comes down to practical factors like storage requirements, dosing preferences, and individual response rather than superior efficacy of either treatment.
Start Your Prescription Weight Loss Journey: Wegovy Access via EverydayMeds
Ready to begin comparing Wegovy and Mounjaro in practice? Complete your clinical assessment at EverydayMeds today, where our qualified prescribers can guide your treatment selection based on your individual circumstances. Starting from £79.99 with transparent pricing and next-day delivery, we've simplified access to these prescription-only medicines through our GPhC-registered pharmacy (#9012878). New customers automatically receive the FIRST40 discount code benefit, whilst returning customers use DOSE25 for continued savings. Our comprehensive support extends beyond dispensing to include injection training, storage guidance, and ongoing clinical oversight throughout your weight management journey. Take the first step towards your prescription weight loss goals with professional guidance and premium pharmaceutical care at EverydayMeds.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
